OTHER TRANSACTION AGREEMENT (OTA) BETWEEN THE MEDICINES COMPANY 8 SYLVAN WAY PARSIPPANY, NEW JERSEY, 07054 AND THE UNITED STATES OF AMERICA DEPARTMENT OF HEALTH AND HUMAN SERVICES ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE WASHINGTON, DC 20201Confidential Materials • October 27th, 2016 • Medicines Co /De • Pharmaceutical preparations
This Agreement is entered into between the United States of America, hereinafter called the Government, represented by the Department of Health and Human Services (DHHS) and The Medicines Company, pursuant to and under U.S. Federal law.
MANUFACTURING AND SUPPLY AGREEMENTConfidential Materials • November 9th, 2007 • Critical Therapeutics Inc • Pharmaceutical preparations • England
This MANUFACTURING & SUPPLY AGREEMENT (this “Agreement”), dated as of August 20, 2007 by and among (i) Critical Therapeutics, Inc. , a Delaware corporation having a place of business at 60 Westview Street, Lexington, MA 02421, USA (“CRTX”), (ii) Jagotec AG, a Swiss company having a place of business at Eptingerstrasse 51, CH-4132 Muttenz, Switzerland (“Jagotec”) and (iii) for the purposes of clause 20 only, SkyePharma PLC, an English company having a place of business at 105 Piccadilly, London W1J 7NJ (Jagotec and CRTX individually referred to as a “Party” and together as the “Parties”).
AMENDMENT TO CONFIRMATIONConfidential Materials • June 28th, 2006 • Medtronic Inc • Electromedical & electrotherapeutic apparatus • New York
WHEREAS, Dealer and Issuer are parties to a Confirmation dated as of April 12, 2006 (Transaction Reference Number: _______________) (the “Confirmation”);
MASTER SERVICES AGREEMENT (MSA)Confidential Materials • March 1st, 2017 • Genpact LTD • Services-management consulting services • New York
THIS MSA is made by and between the following parties (each individually referred to as a “Party” and jointly as “the Parties”) and is effective as of: January 1, 2017 (the “Effective Date”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.Confidential Materials • March 7th, 2008 • NxStage Medical, Inc. • Electromedical & electrotherapeutic apparatus • Delaware
This Agreement (this “Agreement”) is made as of January 7, 2008 (the “Effective Date”), by and between Medisystems Corporation, a Washington corporation (“MDS”), and DaVita Inc., a Delaware corporation (“DVA”). NxStage Medical, Inc., a Delaware corporation (“NxStage”), is a party to this Agreement solely for purposes of agreeing to the provisions of Section 11.1.
ContractConfidential Materials • May 10th, 2017 • Argos Therapeutics Inc • Pharmaceutical preparations
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. Exhibit 10.6
FIRST AMENDMENT TO CO-DEVELOPMENT AND COLLABORATION AGREEMENTConfidential Materials • November 4th, 2016 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations
This First Amendment (“First Amendment”) is made effective as of October 14, 2016 (“Amendment Effective Date”) and shall serve to modify that certain Co-Development and Collaboration Agreement dated April 9, 2014 (“Agreement”) by and between AVEO Pharmaceuticals, Inc. (“AVEO”) and Biodesix, Inc. (“Biodesix”). AVEO and Biodesix are sometimes referred to individually as a “Party” and collectively as the “Parties”.
